drugset / Trial / NCT00128700

Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00128700

RandomizedOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Vatalanib may stop the growth of tumor cells by blocking blood flow to the tumor. Giving temozolomide and radiation therapy together with vatalanib may kill more tumor cells. PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of vatalanib when given together with temozolomide and radiation therapy and to see how well they work in treating patients with newly diagnosed glioblastoma multiforme.

Timeline

Start
2005-06
Primary completion
2007-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Temozolomide Small molecule Oral
Subject vatalanib Small molecule 500 mg
Subject vatalanib Small molecule 750 mg
Subject vatalanib Small molecule 1000 mg
Subject vatalanib Small molecule 1250 mg